Christopher Gallagher
MedStar Washington Hospital Center
22 Papers
35 Citations
Christopher Gallagher is an academic researcher from MedStar Washington Hospital Center. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 7, co-authored 17 publications. Previous affiliations of Christopher Gallagher include Washington Cancer Institute.
Chat about Author
Papers
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
Filipa Lynce,Ana Barac,X. Geng,Chau T. Dang,Anthony F. Yu,Anthony F. Yu,Karen L. Smith,Christopher Gallagher,Paula R. Pohlmann,Raquel Nunes,P. Herbolsheimer,Robert D. Warren,Monvadi B. Srichai,Mark Hofmeyer,A. Cunningham,P. Timothee,Federico M. Asch,Ayesha N. Shajahan-Haq,Ming Tony Tan,Claudine Isaacs,Sandra M. Swain +20 more
TL;DR: This study provides safety data of HER2-targeted therapies in patients with breast cancer and reduced LVEF while receiving cardioprotective medications and close cardiac monitoring and demonstrates the importance of collaboration between cardiology and oncology providers to allow for delivery of optimal oncologic care.
Video intervention increases participation of black breast cancer patients in therapeutic trials.
Brandi N. Robinson,Brandi N. Robinson,Antoinette F. Newman,Antoinette F. Newman,Eshetu Tefera,P. Herbolsheimer,Raquel Nunes,Christopher Gallagher,Pamela Randolph-Jackson,Adedamola Omogbehin,Asma Dilawari,Paula R. Pohlmann,Mahsa Mohebtash,Young Lee,Yvonne Ottaviano,Avani Mohapatra,Filipa Lynce,Filipa Lynce,Richard A. Brown,Mihriye Mete,Sandra M. Swain,Sandra M. Swain +21 more
- 18 Sep 2017
TL;DR: The findings suggest the promising utility of a culturally tailored video intervention for improving black patients’ attitudes regarding clinical trial participation and resultant enrollment and the need for population-specific recruitment efforts.
28
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.
Sagar Sardesai,Alexandra Thomas,Christopher Gallagher,Filipa Lynce,Yvonne L. Ottaviano,Tarah J. Ballinger,Bryan P. Schneider,Anna Maria Storniolo,Amber Bauchle,Sandra K. Althouse,Susan M. Perkins,Andrea R. Masters,Robert E. Stratford,Zizheng Dong,Jing-Yuan Liu,Jian-Ting Zhang,Kathy D. Miller +16 more
TL;DR: Omeprazole 80 mg orally twice daily for 4-7 days prior to neoadjuvant anthracycline-taxane-based chemotherapy (AC-T) and continued until surgery as mentioned in this paper.
28
Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military
Christina Brzezniak,Sacha Satram-Hoang,Hans-Peter Goertz,Carolina Reyes,Ashok Gunuganti,Christopher Gallagher,Corey A. Carter +6 more
TL;DR: The lack of significant outcome disparity between AAs and Caucasians and the earlier stage at diagnosis than usually seen in civilian populations suggest that equal access to healthcare may play a role in early detection and survival.
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
Katia E. Khoury,Katia E. Khoury,Filipa Lynce,Filipa Lynce,Ana Barac,Xue Geng,Chau T. Dang,Anthony F. Yu,Karen L. Smith,Christopher Gallagher,Paula R. Pohlmann,Raquel Nunes,P. Herbolsheimer,Robert D. Warren,Monvadi B. Srichai,Mark Hofmeyer,Federico M. Asch,Ming Tan,Claudine Isaacs,Claudine Isaacs,Sandra M. Swain,Sandra M. Swain +21 more
TL;DR: The SAFE-HEaRt trial as mentioned in this paper was designed to evaluate the safety of HER2-targeted therapy for breast cancer patients with compromised heart function at a median follow-up of 3.5 years.
22